Liposome-coated lipoplex–based carrier for antisense oligonucleotides

Cancer Biology and Therapy

Volumn 16, Issue 1, 2015, Pages 66-76

  Wyrozumska, Paulina ^a   Meissner, Justyna ^a   Toporkiewicz, Monika ^a   Szarawarska, Marta ^a   Kuliczkowski, Kazimierz ^b   Ugorski, Maciej ^c   Walasek, Marta A ^a   Sikorski, Aleksander F ^a  

^a UNIVERSITY OF WROC AW   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c WROC AW UNIVERSITY OF ENVIRONMENTAL AND LIFE SCIENCES   (Poland)

Author keywords

acute leukemia; antisense deoxynucleotides; BCL 2 gene; cationic lipids; gene therapy; lipid carrier; lipoplex; liposome coated lipoplex

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE; LIPOPLEX; LIPOSOME; MESSENGER RNA; PLASMID DNA; PROTEIN BCL 2; DRUG CARRIER;

ADULT; ANIMAL EXPERIMENT; ANTISENSE THERAPY; ARTICLE; CELL SURVIVAL RATE; CONTROLLED STUDY; DAUDI CELL LINE; DRUG COATING; FEMALE; GENE PRODUCT; GENETIC TRANSFECTION; GENOTYPE; HEMOLYSIS; HL-60 CELL LINE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; JURKAT CELL LINE; LIPID COMPOSITION; MALE; MOUSE; NONHUMAN; PLASMID; TUMOR ENGRAFTMENT; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; CELL SURVIVAL; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; DRUG STABILITY; GENETICS; PROTO ONCOGENE; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DRUG CARRIERS; DRUG STABILITY; FEMALE; GENES, BCL-2; HUMANS; LIPOSOMES; MALE; MICE; OLIGONUCLEOTIDES, ANTISENSE; TISSUE DISTRIBUTION; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84939789246     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/15384047.2014.987009     Document Type: Article

References (29)

1. Nienhuis AW. Development of gene therapy for blood disorders. Blood 2008; 111:4431-44; PMID:18441245; http://dx.doi.org/10.1182/blood-2007-11-078121
2. Tagami T, Suzuki T, Matsunaga M, Nakamura K, Moriyoshi N, Ishida T, Kiwada H. Anti-angiogenic therapy via cationic liposome-mediated systemic siRNA delivery. Int J Pharm 2012; 422:280-9; PMID:22101286; http://dx.doi.org/10.1016/j.ijpharm.2011.10.059
3. Kurosaki T, Kitahara T, Kawakami S, Higuchi Y, Yamaguchi A, Nakagawa H, Kodama Y, Hamamoto T, Hashida M, Sasaki H. Gamma-polyglutamic acid-coated vectors for effective and safe gene therapy. J Control Release 2010; 142:404-10; PMID:19931327; http://dx.doi.org/10.1016/j.jconrel.2009.11.010
4. Zhao X, Pan F, Holt CM, Lewis AL, Lu JR. Controlled delivery of antisense oligonucleotides: a brief review of current strategies. Expert Opin Drug Deliv 2009; 6:673-86; PMID:19552611; http://dx.doi.org/10.1517/17425240902992894
5. Wyrozumska P, Stebelska K, Grzybek M, Sikorski AF. Synthetic Vectors for the genetic drug delivery. In: Mozafari MR, ed. Nanocarriers Technologies: Frontiers of Nanotheraphy. Dordrecht, The Netherlands: Springer 2006:139-74.
6. Oh YK, Park TG. siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev 2009; 61:850-62; PMID:19422869; http://dx.doi.org/10.1016/j.addr.2009.04.018
7. Grijalvo S, Avino A, Eritja R. Oligonucleotide delivery: a patent review (2010–2013). Expert Opin Ther Pat 2014; 24:801-19; PMID:24798406; http://dx.doi.org/10.1517/13543776.2014.915944
8. Chang RS, Suh MS, Kim S, Shim G, Lee S, Han SS, Lee KE, Jeon H, Choi HG, Choi Y, et al. Cationic drug-derived nanoparticles for multifunctional delivery of anticancer siRNA. Biomaterials 2011; 32:9785-95; PMID:21937102; http://dx.doi.org/10.1016/j.biomaterials.2011.09.017
9. Hoekstra D, Rejman J, Wasungu L, Shi F, Zuhorn I. Gene delivery by cationic lipids: in and out of an endosome. Biochem Soc Trans 2007; 35:68-71; PMID:17233603; http://dx.doi.org/10.1042/BST0350068
10. Stuart DD, Allen TM. A new liposomal formulation for antisense oligodeoxynucleotides with small size, high incorporation efficiency and good stability. Biochim Biophys Acta 2000; 1463:219-29; PMID:10675501; http://dx.doi.org/10.1016/S0005-2736(99)00209-6
11. Bartsch M, Weeke-Klimp AH, Hoenselaar EP, Stuart MC, Meijer DK, Scherphof GL, Kamps JA. Stabilized lipid coated lipoplexes for the delivery of antisense oligonucleotides to liver endothelial cells in vitro and in vivo. J Drug Target 2004; 12:613-21; PMID:15621687; http://dx.doi.org/10.1080/10611860400013519
12. Stuart DD, Semple SC, Allen TM. High efficiency entrapment of antisense oligonucleotides in liposomes. Methods Enzymol 2004; 387:171-88; PMID:15172164; http://dx.doi.org/10.1016/S0076-6879(04)87011-3
13. Shen JZ, Zhang YY, Fu HY, Wu DS, Zhou HR. Overexpression of microRNA-143 inhibits growth and induces apoptosis in human leukemia cells. Oncol Rep 2014; 31:2035-42; PMID:24626955
14. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9:47-59; PMID:18097445; http://dx.doi.org/10.1038/nrm2308
15. Robak T, Wierzbowska A. Current and emerging therapies for acute myeloid leukemia. Clin Ther 2009; 31 Pt 2:2349-70; PMID:20110045; http://dx.doi.org/10.1016/j.clinthera.2009.11.017
16. -2/Bax and Ras/Raf/MEK/ERK signaling pathways: implications in pediatric leukemia pathogenesis and new prospects for therapeutic approaches. Expert Rev Hematol 2013; 6:587-97; PMID:24083449; http://dx.doi.org/10.1586/17474086.2013.827415
17. -2 family proteins for treatment of acute leukaemia. Gen Physiol Biophys 2011; 30 Spec No:S3-S12; PMID:21869449; http://dx.doi.org/10.4149/gpb_2011_SI1_3
18. -2 family proteins in chronic lymphocytic leukaemia. Leuk Res 2010; 34:837-42; PMID:20359747; http://dx.doi.org/10.1016/j.leukres.2010.03.011
19. -2-targeted antisense therapy (Oblimersen sodium): towards clinical reality. Rev Recent Clin Trials 2006; 1:217-35; PMID:18473975; http://dx.doi.org/10.2174/157488706778250050
20. -2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood 2002; 99:3461-4; PMID:11964319; http://dx.doi.org/10.1182/blood.V99.9.3461
21. Rong YP, Aromolaran AS, Bultynck G, Zhong F, Li X, McColl K, Matsuyama S, Herlitze S, Roderick HL, Bootman MD, et al. Targeting Bcl-2-IP3 receptor interaction to reverse Bcl-2's inhibition of apoptotic calcium signals. Mol Cell 2008; 31:255-65; PMID:18657507; http://dx.doi.org/10.1016/j.molcel.2008.06.014
22. Fulda S. Inhibitor of apoptosis proteins in pediatric leukemia: molecular pathways and novel approaches to therapy. Front Oncol 2014; 4:3; PMID:24478984; http://dx.doi.org/10.3389/fonc.2014.00003
23. Dubielecka PM, Jazwiec B, Potoczek S, Wrobel T, Miloszewska J, Haus O, Kuliczkowski K, Sikorski AF. Changes in spectrin organisation in leukaemic and lymphoid cells upon chemotherapy. Biochem Pharmacol 2005; 69:73-85; PMID:15588716; http://dx.doi.org/10.1016/j.bcp.2004.08.031
24. Siwak DR, Tari AM, Lopez-Berestein G. Liposomal antisense oligonucleotides for cancer therapy. Methods Enzymol 2004; 387:241-53; PMID:15172168; http://dx.doi.org/10.1016/S0076-6879(04)87015-0
25. -2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann Oncol 2002; 13:539-45; PMID:12056703; http://dx.doi.org/10.1093/annonc/mdf124
26. -2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol 2004; 22:1110-7; PMID:15020613; http://dx.doi.org/10.1200/JCO.2004.10.148
27. -2 antisense g3139 in cultured cells and treated patients with acute myeloid leukemia. Clin Cancer Res 2005; 11:2998-3008; PMID:15837754; http://dx.doi.org/10.1158/1078-0432.CCR-04-1505
28. Reimer DL, Zhang Y, Kong S, Wheeler JJ, Graham RW, Bally MB. Formation of novel hydrophobic complexes between cationic lipids and plasmid DNA. Biochemistry 1995; 34:12877-83; PMID:7548044; http://dx.doi.org/10.1021/bi00039a050
29. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 1979; 76:4350-4; PMID:388439; http://dx.doi.org/10.1073/pnas.76.9.4350